辅助甲福明可以减少被诊断为精神分裂症的患者在 olanzapine 诱导的代谢副作用吗?
1Kent and Medway Medical School, University of Kent, Canterbury, UK.
Neuropsychopharmacology reports
|September 25, 2025
概括
梅特福明除了奥兰扎平治疗外,还能持续地控制体重,胰岛素抵抗,甘油三和肝脂肪. 需要进一步的研究来确定最佳剂量和对不同患者群体的影响.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢医学是一种代谢医学.
- 精神病学是一个精神病学.
背景情况:
- 奥兰沙平是一种非典型的抗精神病药物,有效治疗精神分裂症和双相情感障碍,但会导致显著的代谢副作用,如体重增加和胰岛素抵抗.
- 这些由 olanzapine 诱导的代谢问题有助于代谢综合征,需要策略来减轻这些副作用.
- 本系统性审查审查了甲福明作为辅助疗法的疗效,以抵消奥兰扎的代谢后果.
研究的目的:
- 系统地审查现有证据,以证实甲福尔在减少奥兰扎宾诱导的代谢不良影响方面的有效性.
- 评估辅助甲福明对患者体重,葡萄糖代谢和脂质概况的影响.
- 确定当前研究中关于甲福明在治疗奥兰扎平相关代谢综合征中的作用的缺陷.
主要方法:
- 使用PICO框架和四个数据库的严格搜索策略进行了叙事综合系统审查.
- 在选择文章时,遵循了PRISMA指南,从71篇文章开始,根据严格的包含/排除标准缩小至6篇.
- 包括体重/BMI,腰围,葡萄糖/胰岛素水平和脂质配置文件在内的关键结果被提取并进行叙述性分析.
主要成果:
- 辅助甲福明在减少与奥兰扎相关的体重增加/BMI,甘油三,肝脂肪含量和胰岛素抵抗方面显示出显著的益处.
- 甲福明对腰围或某些脂质参数 (如LDL和总胆固醇) 没有显著影响.
- 该审查强调缺乏高质量的随机对照试验 (RCT) 关于剂量依赖效应和人口统计学变异.
结论:
- 甲福明有效地控制了 olanzapine 的关键代谢副作用,包括体重增加,胰岛素耐药性和脂质失调症.
- 在腰围和一些脂质参数上观察到可变效应,表明需要进一步调查.
- 建议包括对不同人群进行更大,更长的RCT和不同剂量的甲福明,以建立最终的指导方针.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Psychosis: Goals of Pharmacotherapy
474
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
474
Antidepressant Drugs: MAOIs and Other Agents
828
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
828
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
814
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
814
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
247
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
525
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
525


